ClinicalTrials.gg
RecruitingNCT03316261Updated Dec 17, 2024

Freder1k-Study - Testing Infants for Type 1 Diabetes Risk

An observational study in Identification of Infants at Risk for Type 1 Diabetes, sponsored by Helmholtz Zentrum München. Recruiting at 1 site in Germany. Open to participants aged 1 Day to 6 Weeks, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-12-17.

Sponsored by Helmholtz Zentrum München · Observational

How we know

From the registry’s dates

  • Started Oct 2017; still recruiting 9 years 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Cross-sectional
Enrollment
1,000,000
Ages
1 Day to 6 Weeks
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 294 studies in Diabetes Mellitus, Type 1 with a site in Germany — 22 open to participants now, 30 under way, 6 of them phase 3. Diabetes Mellitus, Type 1 · Germany.

Planned enrollment
Largest of 33
1,000,000 · median 1,000
Started
2017
with 22 others
Observational
33 of 294
8 open now
Primary completion
2027-08
later than 14 of 29 live
Registered
192nd of 294
by date

Among the 294 studies in Diabetes Mellitus, Type 1 with a site in Germany, this one has the largest planned enrollment of the 33 observational ones that give a count, is one of 23 that started in 2017, is one of 33 observational ones, reaches primary completion later than 14 of the 29 other live ones, and was the 192nd registered.

Diabetes Mellitus, Type 1

3,758 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.

Browse Diabetes Mellitus, Type 1 studies →

Open to participants now

22 of the 294 studies in Diabetes Mellitus, Type 1 with a site in Germany are open now. Recruiting first, the newest first:

16 more — sign in →

All 22 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 417 Diabetes Mellitus, Type 1 studies recruiting now, 130 (31%) set no upper age limit and 261 (63%) stop at 75 or younger; 187 take children under 18; 66 take healthy volunteers.

This study: 1 Day to 6 Weeks · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 294 studies in Diabetes Mellitus, Type 1 with a site in Germany, or all of them as a file.
02

Study summary

The Freder1k-Study will identify infants who have a high genetic risk of type 1 diabetes.

Read the detailed description

Type 1 diabetes is a common chronic disease in childhood and is increasing in incidence. Type 1 diabetes is diagnosed by hyperglycemia often in combination with symptoms of weight loss, thirst, fatigue and frequent urination, sometimes with ketoacidosis. The clinical onset is preceded by an asymptomatic phase identified by serum multiple beta-cell autoantibodies. Neonates and infants who are at increased risk to develop multiple beta-cell autoantibodies and type 1 diabetes can now be identified using genetic markers. This provides opportunity for introducing early therapies to prevent beta-cell autoimmunity and type 1 diabetes.

03

Conditions studied

  • Identification of Infants at Risk for Type 1 Diabetes

Keywords

  • infants
  • type 1 diabetes
  • Freder1k
04

Who can participate

Ages eligible
1 Day to 6 Weeks
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Probability sample

Study population

The Freder1k-Study will identify infants who have a high genetic risk of type 1 diabetes.

Inclusion criteria

  • Age: up to age 6 weeks
  • provided written by custodial parent

Exclusion criteria

Exclusion Criteria:

-

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Cross-sectional
Enrollment
1,000,000 participants (estimated)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. greater than 10% risk for multiple beta-cell autoantibodies/type 1 diabetes

    increased risk will be identified by risk scores derived from SNPs

    Time frame: one-time testing before age 6 weeks

07

Study locations

1 of 1 sites recruiting
  • Institut für Diabetesforschung, Helmholtz Zentrum München
    Munich, Germany
    Recruiting
    • Anette-G. Ziegler, Prof. Dr. · Contact
08

References and documents

Publications

  • Hippich M, Holthaus L, Assfalg R, Zapardiel-Gonzalo J, Kapfelsperger H, Heigermoser M, Haupt F, Ewald DA, Welzhofer TC, Marcus BA, Heck S, Koelln A, Stock J, Voss F, Secchi M, Piemonti L, de la Rosa K, Protzer U, Boehmer M, Achenbach P, Lampasona V, Bonifacio E, Ziegler AG. A Public Health Antibody Screening Indicates a 6-Fold Higher SARS-CoV-2 Exposure Rate than Reported Cases in Children. Med. 2021 Feb 12;2(2):149-163.e4. doi: 10.1016/j.medj.2020.10.003. Epub 2020 Oct 29. PubMed 33163984 ↗

Related links

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Oct 2017 (actual). Primary completion is estimated for Aug 2027, 118 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 12, 2017
First posted
Oct 20, 2017
StartActual
Oct 19, 2017
Primary completionEst.
Aug 2027
CompletionEst.
Aug 2027
Last update
Dec 17, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 17, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03316261
Lead sponsor
Helmholtz Zentrum München
Responsible party
Anette-Gabriele Ziegler (Director - Institute of Diabetes Research, Helmholtz Zentrum München) — Principal investigator
First posted
Oct 20, 2017
Start date
Oct 19, 2017
Primary completion
Aug 2027 (estimated)
Completion
Aug 2027 (estimated)
Last update
Dec 17, 2024

Study contacts

Anette-Gabriele Ziegler
Contact
contact@gppad.org
0800-000 0018
Christiane Winkler
Contact
contact@gppad.org
0049-89-31873745
Anette-Gabriele Ziegler
study chair · Helmholtz Zentrum München, IDF-1

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion